Homepage Top Section2

The collaboration follows a successful pilot phase, where XtalPi’s integrated quantum physics and AI algorithms achieved improved hit rates, highlighting the platform’s capability to address the complex metabolic target.

Upon completion of the transaction, Ignite will separate from Aditxt and is expected to become an independent public company via the establishment of a new holding entity, anticipated

The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery and development. Since 2021, Sanofi and Owkin have maintained a

This partnership provides the biopharmaceutical company with early access to the Chai-3 model alongside a dedicated model tailored to Pfizer’s proprietary data and workflows, underscoring a strategic move

The collaboration aims to conduct a full technical and operational assessment of Cellares’ automated manufacturing and testing platforms. This is in preparation for the anticipated demand surrounding TSC-101

This marks the second indication for Aquipta in the EU, where it is now approved both for acute attacks and as a once-daily preventive treatment for adults experiencing

The regulator granted the application priority review for this indication, assigning a Prescription Drug User Fee Act (PDUFA) date of 30 September 2026. Camzyos is currently approved for

The agreement covers Hanmi’s candidate that uses its LAPSCOVERY long-acting platform technology. Sonefpeglutide combines Hanmi’s proprietary technology and has previously achieved approval from the US Food and Drug

The agreement covers antibody-drug conjugates with new payloads and multi-specific antibodies featuring distinct immune-engaging mechanisms. The portfolio consists of eight drug candidates originating from Innovent Biologics and four